bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Authors: Balmanoukian Ani S. , Infante Jeffrey R. , Aljumaily Raid , Naing Aung , Chintakuntlawar Ashish V. , Rizvi Naiyer A. , Ross Helen J. , Gordon Michael , Mallinder Philip R. , Elgeioushi Nairouz , González-García Ignacio , Standifer Nathan , Cann Jennifer , Durham Nicholas , Rahimian Shahram , Kumar Rakesh , Denlinger Crystal S.
Published: April 2023

Patients receiving MEDI1873 at doses ranging from 7.5-25 mg or 75-250 mg were assessed for changes in the soluble factors interferon gamma (IFNy), IFNy-induced protein 10 (IP-10), interferon-inducible T cell alpha chemoattractant(I-TAC), and monokine induced by IFNy (MIG).
Supplementary fig 4 from A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Authors: Wu Annie A. , Bever Katherine M. , Ho Won Jin , Fertig Elana J. , Niu Nan , Zheng Lei , Parkinson Rose M. , Durham Jennifer N. , Onners Beth , Ferguson Anna K. , Wilt Cara , Ko Andrew H. , Wang-Gillam Andrea , Laheru Daniel A. , Anders Robert A. , Thompson Elizabeth D. , Sugar Elizabeth A. , Jaffee Elizabeth M. , Le Dung T.
Published: April 2023

Supplementary fig 4 Changes in the functional markers within each cluster with GVAX + IPI.
Supplementary Tables S1 to S6 from A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Authors: Wu Annie A. , Bever Katherine M. , Ho Won Jin , Fertig Elana J. , Niu Nan , Zheng Lei , Parkinson Rose M. , Durham Jennifer N. , Onners Beth , Ferguson Anna K. , Wilt Cara , Ko Andrew H. , Wang-Gillam Andrea , Laheru Daniel A. , Anders Robert A. , Thompson Elizabeth D. , Sugar Elizabeth A. , Jaffee Elizabeth M. , Le Dung T.
Published: April 2023

Supplementary Tables S1 to S6 clean version.
Supplementary Tables from Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
Authors: Richard François , Majjaj Samira , Venet David , Rothé Françoise , Pingitore Julien , Boeckx Bram , Marchio Caterina , Clatot Florian , Bertucci François , Mariani Odette , Galant Christine , Eynden Gert van den , Salgado Roberto , Biganzoli Elia , Lambrechts Diether , Vincent-Salomon Anne , Pruneri Giancarlo , Larsimont Denis , Sotiriou Christos , Desmedt Christine
Published: April 2023

Supplementary Tables
Supplementary Methods from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplementary Methods
Supplementary Data from Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
Authors: Richard François , Majjaj Samira , Venet David , Rothé Françoise , Pingitore Julien , Boeckx Bram , Marchio Caterina , Clatot Florian , Bertucci François , Mariani Odette , Galant Christine , Eynden Gert van den , Salgado Roberto , Biganzoli Elia , Lambrechts Diether , Vincent-Salomon Anne , Pruneri Giancarlo , Larsimont Denis , Sotiriou Christos , Desmedt Christine
Published: April 2023

Supplementary Data tracked changes
Supplementary Figure 4 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 4: TIL expansion is influenced by the use of feeder cells
Figure S3 from A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma
Authors: Yang Zijian , LaRiviere Michael J. , Ko Jina , Till Jacob E. , Christensen Theresa , Yee Stephanie S. , Black Taylor A. , Tien Kyle , Lin Andrew , Shen Hanfei , Bhagwat Neha , Herman Daniel , Adallah Andrew , O'Hara Mark H. , Vollmer Charles M. , Katona Bryson W. , Stanger Ben Z. , Issadore David , Carpenter Erica L.
Published: April 2023

Figure S3. Multi-analyte panel generation procedure of PDAC/NC diagnosis and occult metastases detection
Supplementary Figure 2 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 2: Tumor antigen reactivity is associated with CD8 +CCR7 -CD45RA-PD-1high cells
Supplementary Data from sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients
Authors: Fane Mitchell E. , Ecker Brett L. , Kaur Amanpreet , Marino Gloria E. , Alicea Gretchen M. , Douglass Stephen M. , Chhabra Yash , Webster Marie R. , Marshall Andrea , Colling Richard , Espinosa Olivia , Coupe Nicholas , Maroo Neera , Campo Leticia , Middleton Mark R. , Corrie Pippa , Xu Xiaowei , Karakousis Giorgos C. , Weeraratna Ashani T.
Published: April 2023

Supplementary Data from sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients
Supplementary Data from Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations
Authors: Aguilera Todd A. , Elghonaimy Eslam A. , Shehade Hussein , Rafat Marjan , Castellini Laura , Jiang Dadi , Kariolis Mihalis , Koong Albert C. , Le Quynh-Thu , Ellies Lesley G. , Rankin Erinn B. , Graves Edward E. , Giaccia Amato J.
Published: April 2023

Supplementary legends and figures
Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

Cytokines and Chemokines
Figure S8 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

YAP requirement in MP41 cells
Figure S4 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Validation of hepatic tumor model
Supplementary fig 3 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Authors: Wu Christina , Williams Terence M. , Robb Ryan , Webb Amy , Wei Lai , Chen Wei , Mikhail Sameh , Ciombor Kristen K. , Cardin Dana B. , Timmers Cynthia , Krishna Somashekar G. , Arnold Mark , Harzman Alan , Abdel-Misih Sherif , Roychowdhury Sameek , Bekaii-Saab Tanios , Wuthrick Evan
Published: April 2023

Supplementary fig 3 Tumor Regression Grade versus Baseline p-ERK score in Tumor Tissue
Figure S2 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Immunofluorescence analysis of autophagy in OMM2.5 cells with or without trametinib
Figure S1 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Galpha and MEK1/2 inhibition in combination with Baf A1 and CQ in MP41 cells
Supplementary Data from Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial
Authors: Multhoff Gabriele , Seier Sophie , Stangl Stefan , Sievert Wolfgang , Shevtsov Maxim , Werner Caroline , Pockley A. Graham , Blankenstein Christiane , Hildebrandt Martin , Offner Robert , Ahrens Norbert , Kokowski Konrad , Hautmann Matthias , Rödel Claus , Fietkau Rainer , Lubgan Dorota , Huber Rudolf , Hautmann Hubert , Duell Thomas , Molls Michael , Specht Hanno , Haller Bernhard , Devecka Michal , Sauter Andreas , Combs Stephanie E.
Published: April 2023

Supplemetary Tables 1-3
Supplementary Data from Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Authors: Middleton Mark R. , McAlpine Cheryl , Woodcock Victoria K. , Corrie Pippa , Infante Jeffrey R. , Steven Neil M. , Evans Thomas R. Jeffry , Anthoney Alan , Shoushtari Alexander N. , Hamid Omid , Gupta Avinash , Vardeu Antonella , Leach Emma , Naidoo Revashnee , Stanhope Sarah , Lewis Sion , Hurst Jacob , O’Kelly Ita , Sznol Mario
Published: April 2023

Supplementary material
Supplementary Figures from Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells
Authors: Scurr Martin J. , Greenshields-Watson Alex , Campbell Emma , Somerville Michelle S. , Chen Yuan , Hulin-Curtis Sarah L. , Burnell Stephanie E.A. , Davies James A. , Davies Michael M. , Hargest Rachel , Phillips Simon , Christian Adam D. , Ashelford Kevin E. , Andrews Robert , Parker Alan L. , Stanton Richard J. , Gallimore Awen , Godkin Andrew
Published: April 2023

Supplementary Figures 1-7
Table S1 from DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas
Authors: Weidema Marije E. , van de Geer Ellen , Koelsche Christian , Desar Ingrid M.E. , Kemmeren Patrick , Hillebrandt-Roeffen Melissa H.S. , Ho Vincent K.Y. , van der Graaf Winette T.A. , Versleijen-Jonkers Yvonne M.H. , von Deimling Andreas , Flucke Uta E.
Published: April 2023

Cluster patient characteristics
Supplemental Figure SF-16 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Network-level analysis of genes correlated with the overall survival (OS) time in Group A indicates that ELAVL1 is a hub protein that interacts with the products of many of these genes.
Supplemental Figure SF-15 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Expanded Pathway-Level Enrichment Analysis of Gene Sets Whose Expression Correlates with Overall Survival in Group A Patients
Supplemental Figure SF-11 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Expression of Many Interleukins (IL) Prognosticates Favorable Survival in Group A and Group B
Supplemental Figure SF-10 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Some TNF Family Expression Prognosticates Favorable Survival in Group A, But Not Group B
Supplemental Figure SF-09 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Some FcR Expression Prognosticates Favorable Survival in Group A, But Not Group B
Supplemental Figure SF-08 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Killer Immunoglobulin-Like Receptors (KIRs) and Killer Cell Lectin-Like Receptors (KLRs) Prognosticate Favorable Survival in Group A, But Not Group B
Supplemental Figure SF-06 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Expression of Immunologic Genes Significantly Predict RFS and OS in Group A, but not in Group B.
Figure S2 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S2
Figure S11 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S11
Supplemental Figure SF-01 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Treatment Schema.
All Supplemental Tables from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Supplemental Tables ST1 to ST14
Supplementary Table 5 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
Authors: Verbeke Delphine , Demeyer Sofie , Prieto Cristina , de Bock Charles E. , De Bie Jolien , Gielen Olga , Jacobs Kris , Mentens Nicole , Verhoeven Bronte Manouk , Uyttebroeck Anne , Boeckx Nancy , De Keersmaecker Kim , Maertens Johan , Segers Heidi , Cools Jan
Published: April 2023

RNA-seq data
Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

Absolute numbers (absolute lymphocyte count * proportion) of designated cell populations at pre-treatment baseline (V1); after the completion of RT/prior to the 3rd dose of immunotherapy (week 6-9, V2); and at the timepoint of first radiographic assessment (Week 10-14, V3). Patients with response (green), stable disease (yellow), and progressive disease (red) outside of the irradiated volume are shown. Symbols reflect unique patients.
Supplementary Table S1 from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Table S1 shows the univariable survival analysis.
Supplementary Figure Legend from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure Legend contains the description of supplementary Figure S1-S4 and supplementary Datasets S1-S2.
Figure S1 from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Figure S1 shows that copy number alterations of well-described prostate cancer tumor suppressor genes are not different between enzalutamide-naïve and -resistant tumors.
Supplemental Table 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Authors: Santa-Maria Cesar A. , Coughlin Janelle W. , Sharma Dipali , Armanios Mary , Blackford Amanda L. , Schreyer Colleen , Dalcin Arlene , Carpenter Ashley , Jerome Gerald J. , Armstrong Deborah K. , Chaudhry Madhu , Cohen Gary I. , Connolly Roisin M. , Fetting John , Miller Robert S. , Smith Karen L. , Snyder Claire , Wolfe Andrew , Wolff Antonio C. , Huang Chiung-Yu , Appel Lawrence J. , Stearns Vered
Published: April 2023

Supplemental Table 1
Supplementary Figures S1-S9 from Autoantibody Landscape in Patients with Advanced Prostate Cancer
Authors: Chen William S. , Haynes Winston A. , Waitz Rebecca , Kamath Kathy , Vega-Crespo Agustin , Shrestha Raunak , Zhang Minlu , Foye Adam , Baselga Carretero Ignacio , Perez Garcilazo Ivan , Zhang Meng , Zhao Shuang G. , Sjöström Martin , Quigley David A. , Chou Jonathan , Beer Tomasz M. , Rettig Matthew , Gleave Martin , Evans Christopher P. , Lara Primo , Chi Kim N. , Reiter Robert E. , Alumkal Joshi J. , Ashworth Alan , Aggarwal Rahul , Small Eric J. , Daugherty Patrick S. , Ribas Antoni , Oh David Y. , Shon John C. , Feng Felix Y.
Published: April 2023

Supplementary Figures S1-S9
Supplementary Table ST6 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Outcome related to location
Supplementary Table ST3 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Resections rates for treatment arms
Supplementary Data from Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study
Authors: Casadei-Gardini Andrea , Marisi Giorgia , Dadduzio Vincenzo , Gramantieri Laura , Faloppi Luca , Ulivi Paola , Foschi Francesco Giuseppe , Tamburini Emiliano , Vivaldi Caterina , Rizzato Mario Domenico , Ielasi Luca , Canale Matteo , Conti Fabio , Rudnas Britt , Fornaro Lorenzo , Silvestris Nicola , Silletta Marianna , Cardellino Giovanni Gerardo , Lonardi Sara , Fornari Francesca , Orsi Giulia , Rovesti Giulia , Zagonel Vittorina , Cascinu Stefano , Scartozzi Mario
Published: April 2023

All Supplementary Data
Supplementary fig 5 from PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Authors: Ahmed Fahad Shabbir , Gaule Patricia , McGuire John , Patel Katir , Blenman Kim , Pusztai Lajos , Rimm David L.
Published: April 2023

Images of PD-L1 expression
Supplementary Table 4 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Supplementary Table 4
Supplementary Figure 4 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Authors: Høgdall Dan , O'Rourke Colm J. , Dehlendorff Christian , Larsen Ole F. , Jensen Lars H. , Johansen Astrid Z. , Dang Hien , Factor Valentina M. , Grunnet Mie , Mau-Sørensen Morten , Oliveira Douglas V.N.P. , Linnemann Dorte , Boisen Mogens K. , Wang Xin W. , Johansen Julia S. , Andersen Jesper B.
Published: April 2023

Supplementary Figure 4: Pathway over-representation analysis of differentially expressed miRNAs across cellular compartments (parent cells, EV) and treatment groups (anti-IL6R (tocilizumab), anti-YKL40) in biliary tract cancer cells in vitro.
Supplementary Figure 5 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

A. Completeness of interval debulking surgery (IDS) according to standardized (std) KELIM value. Wilcoxon P < 0.01. B. Logistic regression curve regarding the probability of complete surgery according to continuous std KELIM values.
Supplementary Data from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Authors: Høgdall Dan , O'Rourke Colm J. , Dehlendorff Christian , Larsen Ole F. , Jensen Lars H. , Johansen Astrid Z. , Dang Hien , Factor Valentina M. , Grunnet Mie , Mau-Sørensen Morten , Oliveira Douglas V.N.P. , Linnemann Dorte , Boisen Mogens K. , Wang Xin W. , Johansen Julia S. , Andersen Jesper B.
Published: April 2023

Supplementary Data, Supplementary Figure Legends, Supplementary Tables
Supplementary Data from Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer
Authors: Schöder Heiko , França Paula Demétrio De Souza , Nakajima Reiko , Burnazi Eva , Roberts Sheryl , Brand Christian , Grkovski Milan , Mauguen Audrey , Dunphy Mark P. , Ghossein Ronald A. , Lyashchenko Serge K. , Lewis Jason S. , O'Donoghue Joseph A. , Ganly Ian , Patel Snehal G. , Lee Nancy Y. , Reiner Thomas
Published: April 2023

Supplementary Data from Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer
Supplementary Data from Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays
Authors: Bouwman Peter , van der Heijden Ingrid , van der Gulden Hanneke , de Bruijn Roebi , Braspenning Merel E. , Moghadasi Setareh , Wessels Lodewyk F.A. , Vreeswijk Maaike P.G. , Jonkers Jos
Published: April 2023

Supplementary Data from Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays
Supplementary Data from Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Authors: Hewitt Susannah L. , Bailey Dyane , Zielinski John , Apte Ameya , Musenge Faith , Karp Russell , Burke Shannon , Garcon Fabien , Mishra Ankita , Gurumurthy Sushma , Watkins Amanda , Arnold Kristen , Moynihan James , Clancy-Thompson Eleanor , Mulgrew Kathy , Adjei Grace , Deschler Katharina , Potz Darren , Moody Gordon , Leinster David A. , Novick Steve , Sulikowski Michal , Bagnall Chris , Martin Philip , Lapointe Jean-Martin , Si Han , Morehouse Chris , Sedic Maja , Wilkinson Robert W. , Herbst Ronald , Frederick Joshua P. , Luheshi Nadia
Published: April 2023

Table S1
Figure S1-S11 from Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Authors: Hewitt Susannah L. , Bailey Dyane , Zielinski John , Apte Ameya , Musenge Faith , Karp Russell , Burke Shannon , Garcon Fabien , Mishra Ankita , Gurumurthy Sushma , Watkins Amanda , Arnold Kristen , Moynihan James , Clancy-Thompson Eleanor , Mulgrew Kathy , Adjei Grace , Deschler Katharina , Potz Darren , Moody Gordon , Leinster David A. , Novick Steve , Sulikowski Michal , Bagnall Chris , Martin Philip , Lapointe Jean-Martin , Si Han , Morehouse Chris , Sedic Maja , Wilkinson Robert W. , Herbst Ronald , Frederick Joshua P. , Luheshi Nadia
Published: April 2023

Supplementary Figures S1-S11
TableS1 from T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Authors: Obradovic Aleksandar Z. , Dallos Matthew C. , Zahurak Marianna L. , Partin Alan W. , Schaeffer Edward M. , Ross Ashley E. , Allaf Mohamad E. , Nirschl Thomas R. , Liu David , Chapman Carolyn G. , O'Neal Tanya , Cao Haiyi , Durham Jennifer N. , Guner Gunes , Baena-Del Valle Javier A. , Ertunc Onur , De Marzo Angelo M. , Antonarakis Emmanuel S. , Drake Charles G.
Published: April 2023

Table S1
Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

Protocol: Data Analysis of Patients Treated Off-protocol
Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

Clinical Study Protocol: A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients with Advanced Cancer
Figure S3 from A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Authors: Romero Joan M. , Grünwald Barbara , Jang Gun-Ho , Bavi Prashant P. , Jhaveri Aaditeya , Masoomian Mehdi , Fischer Sandra E. , Zhang Amy , Denroche Robert E. , Lungu Ilinca M. , De Luca Angela , Bartlett John M.S. , Xu Jing , Li Niandong , Dhaliwal Sharon , Liang Sheng-Ben , Chadwick Dianne , Vyas Foram , Bronsert Peter , Khokha Rama , McGaha Tracy L. , Notta Faiyaz , Ohashi Pamela S. , Done Susan J. , O'Kane Grainne M. , Wilson Julie M. , Knox Jennifer J. , Connor Ashton , Wang Yifan , Zogopoulos George , Gallinger Steven
Published: April 2023

Supplementary Figure 3: Association of chemokine expression with a T cell-inflamed phenotype was validated in a second independent PDAC patient cohort
Table S6 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Authors: Allott Emma H. , Ebot Ericka M. , Stopsack Konrad H. , Gonzalez-Feliciano Amparo G. , Markt Sarah C. , Wilson Kathryn M. , Ahearn Thomas U. , Gerke Travis A. , Downer Mary K. , Rider Jennifer R. , Freedland Stephen J. , Lotan Tamara L. , Kantoff Philip W. , Platz Elizabeth A. , Loda Massimo , Stampfer Meir J. , Giovannucci Edward , Sweeney Christopher J. , Finn Stephen P. , Mucci Lorelei A.
Published: April 2023

Age-adjusted gene set enrichment analysis showing the top ten gene sets upregulated and downregulated in prostate tumor tissue of ever (n=30) versus never (n=199) statin users, ordered by the normalized enrichment score
Supplementary Figure 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

Dose modifications: vorinostat and sirolimus
Table S5 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Authors: Allott Emma H. , Ebot Ericka M. , Stopsack Konrad H. , Gonzalez-Feliciano Amparo G. , Markt Sarah C. , Wilson Kathryn M. , Ahearn Thomas U. , Gerke Travis A. , Downer Mary K. , Rider Jennifer R. , Freedland Stephen J. , Lotan Tamara L. , Kantoff Philip W. , Platz Elizabeth A. , Loda Massimo , Stampfer Meir J. , Giovannucci Edward , Sweeney Christopher J. , Finn Stephen P. , Mucci Lorelei A.
Published: April 2023

Leading edge genes in the T cell receptor-signaling pathway, the top-ranking pathway in tumor-adjacent normal prostate tissue differentially expressed in ever versus never statin users, as identified by age-adjusted gene set enrichment analysis
Table S3 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

Treatment Related Adverse Events by Grade
Figure S6 from Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Pocha Kolja , Mock Andreas , Rapp Carmen , Dettling Steffen , Warta Rolf , Geisenberger Christoph , Jungk Christine , Martins Leila R. , Grabe Niels , Reuss David , Debus Juergen , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel C.
Published: April 2023

Details on the gene expression, single-cell sequencing, and copy number alteration data.
Figure S4 from Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Pocha Kolja , Mock Andreas , Rapp Carmen , Dettling Steffen , Warta Rolf , Geisenberger Christoph , Jungk Christine , Martins Leila R. , Grabe Niels , Reuss David , Debus Juergen , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel C.
Published: April 2023

Boxplots comparing the infiltration of TIL subsets for preoperative treatments (chemotherapy or other systemic therapy) as well as for the comparison of synchronous vs. metachronous brain metastases.
Supplementary Figure S2 from Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Fraunhoffer Nicolas A. , Abuelafia Analía Meilerman , Bigonnet Martin , Gayet Odile , Roques Julie , Telle Emmanuel , Santofimia-Castaño Patricia , Borrello María Teresa , Chuluyan Eduardo , Dusetti Nelson , Iovanna Juan
Published: April 2023

Supplementary Figure S2
Supplementary Table 3 from A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Authors: Pishvaian Michael J. , Wang Hongkun , He Aiwu Ruth , Hwang Jimmy J. , Smaglo Brandon G. , Kim Sunnie S. , Weinberg Benjamin A. , Weiner Louis M. , Marshall John L. , Brody Jonathan R.
Published: April 2023

Veliparib pharmacokinetics compared to historical control.
Table S1 from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Authors: Cooper Alissa J. , Kobayashi Yoshihisa , Kim Dewey , Clifford Sarah E. , Kravets Sasha , Dahlberg Suzanne E. , Chambers Emily S. , Li Jiaqi , Rangachari Deepa , Nguyen Tom , Costa Daniel B. , Rabin Michael S. , Wagle Nikhil , Sholl Lynette M. , Jänne Pasi A , Oxnard Geoffrey R.
Published: April 2023

SgRNAs, primers, and antibodies used in this study
Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Authors: Hong David S. , Concin Nicole , Vergote Ignace , de Bono Johann S. , Slomovitz Brian M. , Drew Yvette , Arkenau Hendrik-Tobias , Machiels Jean-Pascal , Spicer James F. , Jones Robert , Forster Martin D. , Cornez Nathalie , Gennigens Christine , Johnson Melissa L. , Thistlethwaite Fiona C. , Rangwala Reshma A. , Ghatta Srinivas , Windfeld Kristian , Harris Jeffrey R. , Lassen Ulrik Niels , Coleman Robert L.
Published: April 2023

Supplementary Data
Supplementary Fig. S5 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

Kaplan-Meier curves for PFS according to ALK fusion variants in patients who received alectinib as the first TKI treatment. Kaplan-Meier curves for PFS stratified by EML4-ALK variant 1 (v1), variant 3 (v3), variant 2 (v2) and other ALK fusion variants (A) or by variant 1 and non-variant 1 (non-v1) (B).
Table S2 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary Table S2. Detailed patient characteristics at baseline, during anti-PD-1/PD-L1 therapy, and in follow-up
Figure S2 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary Figure S2. Impact of TIL characteristics on anti-PD-1/PD-L1 treatment response of MCC patients.
Table S5 from Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Authors: Guerini-Rocco Elena , Gray Kathryn P. , Fumagalli Caterina , Reforgiato Marta Rita , Leone Isabella , Rafaniello Raviele Paola , Munzone Elisabetta , Kammler Roswitha , Neven Patrick , Hitre Erika , Jerusalem Guy , Simoncini Edda , Gombos Andrea , Deleu Ines , Karlsson Per , Aebi Stefan , Chirgwin Jacquie , Di Lauro Vincenzo , Thompson Alastair , Graas Marie-Pascale , Barber Matthew , Fontaine Christel , Loibl Sibylle , Gavilá Joaquín , Kuroi Katsumasa , Müller Bettina , O’Reilly Seamus , Di Leo Angelo , Goldhirsch Aron , Viale Giuseppe , Barberis Massimo , Regan Meredith M. , Colleoni Marco
Published: April 2023

Clinico-pathologic characteristics of patients according to FGFR1 CNG status.
Supplementary Figure S2 from Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Authors: Guo Jimmy A. , Hoffman Hannah I. , Shroff Stuti G. , Chen Peter , Hwang Peter G. , Kim Daniel Y. , Kim Daniel W. , Cheng Stephanie W. , Zhao Daniel , Mahal Brandon A. , Alshalalfa Mohammed , Niemierko Andrzej , Wo Jennifer Y. , Loeffler Jay S. , Fernandez-del Castillo Carlos , Jacks Tyler , Aguirre Andrew J. , Hong Theodore S. , Mino-Kenudson Mari , Hwang William L.
Published: April 2023

Supplementary Figure S2
Supplementary Data Legends from Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Authors: Guo Jimmy A. , Hoffman Hannah I. , Shroff Stuti G. , Chen Peter , Hwang Peter G. , Kim Daniel Y. , Kim Daniel W. , Cheng Stephanie W. , Zhao Daniel , Mahal Brandon A. , Alshalalfa Mohammed , Niemierko Andrzej , Wo Jennifer Y. , Loeffler Jay S. , Fernandez-del Castillo Carlos , Jacks Tyler , Aguirre Andrew J. , Hong Theodore S. , Mino-Kenudson Mari , Hwang William L.
Published: April 2023

Supplementary Data Legends
Supplementary Figure 7 from Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice
Authors: Zhang Ian Y. , Zhou Hui , Liu Huili , Zhang Leying , Gao Hang , Liu Shunan , Song Yanyan , Alizadeh Darya , Yin Hongwei Holly , Pillai Raju , Badie Behnam
Published: April 2023

Supplementary Figure 7
Supplementary Data Captions from Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice
Authors: Zhang Ian Y. , Zhou Hui , Liu Huili , Zhang Leying , Gao Hang , Liu Shunan , Song Yanyan , Alizadeh Darya , Yin Hongwei Holly , Pillai Raju , Badie Behnam
Published: April 2023

Supplementary Data Captions
Supplementary Figure 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
Authors: LeBlanc Amy K. , Mazcko Christina N. , Cherukuri Aswini , Berger Erika P. , Kisseberth William C. , Brown Megan E. , Lana Susan E. , Weishaar Kristen , Flesner Brian K. , Bryan Jeffrey N. , Vail David M. , Burton Jenna H. , Willcox Jennifer L. , Mutsaers Anthony J. , Woods J. Paul , Northrup Nicole C. , Saba Corey , Curran Kaitlin M. , Leeper Haley , Wilson-Robles Heather , Wustefeld-Janssens Brandan G. , Lindley Stephanie , Smith Annette N. , Dervisis Nikolaos , Klahn Shawna , Higginbotham Mary Lynn , Wouda Raelene M. , Krick Erika , Mahoney Jennifer A. , London Cheryl A. , Barber Lisa G. , Balkman Cheryl E. , McCleary-Wheeler Angela L. , Suter Steven E. , Martin Olya , Borgatti Antonella , Burgess Kristine , Childress Michael O. , Fidel Janean L. , Allstadt Sara D. , Gustafson Daniel L. , Selmic Laura E. , Khanna Chand , Fan Timothy M.
Published: April 2023

Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.
Supplementary Figures from Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma
Authors: Marostica Eliana , Barber Rebecca , Denize Thomas , Kohane Isaac S. , Signoretti Sabina , Golden Jeffrey A. , Yu Kun-Hsing
Published: April 2023

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5
Supplementary Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Authors: Budden Timothy , Gaudy-Marqueste Caroline , Craig Sarah , Hu Yuan , Earnshaw Charles H. , Gurung Shilpa , Ra Amelle , Akhras Victoria , Shenjere Patrick , Green Ruth , Jamieson Lynne , Lear John , Motta Luisa , Caulín Carlos , Oudit Deemesh , Furney Simon J. , Virós Amaya
Published: April 2023

SF1, SF2 Supp Methods Supp Table Legends
Figure S2 from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Authors: Kazmi Farasat , Nicum Shibani , Roux Rene L. , Spiers Laura , Gnanaranjan Chat , Sukumaran Ajithkumar , Gabra Hani , Ghazaly Essam , McCracken Nigel W. , Harrison David J. , Blagden Sarah P.
Published: April 2023

GOF plots of observed versus individual model fitted concentrations
Supplementary Data 2 from Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Authors: Hackeng Wenzel M. , Dreijerink Koen M.A. , de Leng Wendy W.J. , Morsink Folkert H.M. , Valk Gerlof D. , Vriens Menno R. , Offerhaus G. Johan A. , Geisenberger Christoph , Brosens Lodewijk A.A.
Published: April 2023

NEN-ID probe importance
Supplemental Figure 1 from Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Authors: Xie Hao , Mahoney Douglas W. , Foote Patrick H. , Burger Kelli N. , Doering Karen A. , Taylor William R. , Then Sara S. , Cao Xiaoming , McGlinch Maria , Berger Calise K. , Wu Tsung-Teh , Hubbard Joleen M. , Allawi Hatim T. , Kaiser Michael W. , Lidgard Graham P. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 1: The average level of all MDMs assayed from DNA extracted from primary and metastatic CRC tissues was not significantly different in Primary and Metastatic Tissue MDM Concordance Study. (A) Average level of all MDMs in metachronous metastatic CRC and the corresponding primary CRC as well as in synchronous metastatic CRC and the corresponding primary CRC; (B) The difference of average level of all MDMs in paired primary and metachronous metastatic CRC as well as in paired primary and synchronous metastatic CRC. MDM: methylated DNA marker; CRC: colorectal cancer.